Hackensack Meridian Health

Canary Speech is a technology company specializing in AI-driven vocal digital biomarkers for health monitoring through conversational speech. Its innovative technology allows for the analysis of voice as a vital sign, enabling clinicians to detect stress, mood, and energy levels within just 20 seconds of speech. This proactive approach facilitates the early identification of neurological and cognitive diseases, including Parkinson's, dementia, and Alzheimer's. By utilizing its patented vocal biomarker technology, Canary Speech provides critical insights that can lead to timely interventions, thereby reducing hospital readmissions and preventing unnecessary hospitalizations. The company’s research extends to simulating various health conditions, highlighting its potential for broad applications in early diagnosis and monitoring of cognitive health.

FluidForm Bio is a biotechnology company focused on creating living human tissue to improve disease treatment. Utilizing its patented FRESH technology, the company employs 3D printing to construct tissue using cells, proteins, and no other materials. This innovative platform has been validated through partnerships with leading life science companies, enabling the production of high-quality tissue for various applications. FluidForm Bio's advanced techniques integrate breakthroughs in 3D printing, computational and synthetic biology, artificial intelligence, and materials science to deliver human tissue that closely resembles natural tissue. Established in 2018 and headquartered in Waltham, Massachusetts, FluidForm Bio aims to provide transformative therapies that offer better treatment options for patients in need.

Med-Metrix specializes in providing Performance Management and Revenue Cycle solutions tailored for the healthcare industry. The company’s services encompass patient intake, revenue integrity, collections, and business insights, all aimed at enhancing the productivity and financial performance of healthcare systems, hospitals, and providers. Utilizing its proprietary FLOWtechnology platform, Med-Metrix offers graphic-rich reporting and automated workflows, complemented by advisory and outsourcing services as necessary. This integrated approach enables clients to improve patient experiences while effectively increasing revenue collections.

EpiBone is a biotechnology company specializing in regenerative medicine for bone repair. It uses patient-specific stem cells and 3D fabrication to create living, anatomically precise bone grafts. The company's lead product has completed Phase I/IIa clinical trials, with additional products focusing on cartilage repair under development.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.